NEOS Investment Management LLC Buys 2,894 Shares of Biogen Inc. $BIIB

NEOS Investment Management LLC lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 13.9% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 23,734 shares of the biotechnology company’s stock after buying an additional 2,894 shares during the period. NEOS Investment Management LLC’s holdings in Biogen were worth $5,128,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Biogen during the second quarter valued at about $3,453,878,000. Primecap Management Co. CA acquired a new position in shares of Biogen in the second quarter valued at approximately $3,274,304,000. Norges Bank acquired a new position in shares of Biogen in the fourth quarter valued at approximately $464,408,000. Boston Partners bought a new position in Biogen in the 4th quarter valued at approximately $302,815,000. Finally, Legal & General Group Plc acquired a new stake in Biogen during the 2nd quarter worth approximately $322,640,000. 87.93% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on BIIB shares. Weiss Ratings lowered shares of Biogen from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, August 12th. Wolfe Research raised shares of Biogen from a “peer perform” rating to an “outperform” rating and set a $300.00 price target for the company in a research note on Thursday, August 13th. Wall Street Zen lowered shares of Biogen from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Canaccord Genuity Group boosted their price objective on shares of Biogen from $245.00 to $248.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Finally, Wedbush increased their price objective on Biogen from $201.00 to $215.00 and gave the company a “neutral” rating in a report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $228.50.

Biogen Price Performance

Biogen stock opened at $220.83 on Monday. The firm has a market cap of $32.63 billion, a price-to-earnings ratio of 39.08, a PEG ratio of 2.44 and a beta of 0.17. Biogen Inc. has a 52-week low of $135.39 and a 52-week high of $225.80. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87. The firm has a 50 day moving average price of $209.53 and a two-hundred day moving average price of $196.62.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The company had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. During the same period in the prior year, the firm posted $5.47 EPS. The company’s quarterly revenue was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities analysts predict that Biogen Inc. will post 12.39 EPS for the current year.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Long-term Dravet syndrome data support zorevunersen. Biogen and Stoke Therapeutics reported four-year Phase 1/2a extension data showing durable seizure reductions, including reductions in severe seizure types associated with sudden unexpected death in epilepsy, as well as continued improvements in cognition, behavior and quality of life. The results strengthen the potential for zorevunersen to become a disease-modifying treatment, though it remains investigational. Stoke and Biogen unveil long-term zorevunersen data
• Positive Sentiment: LEQEMBI gained a major China regulatory approval. China’s National Medical Products Administration approved the once-weekly subcutaneous autoinjector formulation of LEQEMBI for initiation treatment in early Alzheimer’s disease. At-home dosing could improve patient convenience, reduce infusion-center burdens and broaden adoption in a large and growing market. Eisai leads development and commercialization, with Biogen sharing economics under their collaboration. Biogen and Eisai announce China LEQEMBI approval
• Positive Sentiment: U.S. patients can now access weekly at-home LEQEMBI injections. Biogen and Eisai launched LEQEMBI IQLIK in the United States for eligible early Alzheimer’s patients, offering initiation and maintenance treatment through a pre-filled syringe or autoinjector. The new delivery option may lower barriers to treatment and support future product demand.
• Neutral Sentiment: Investors are assessing valuation after a strong rally. A valuation analysis argued that BIIB could be materially below estimated discounted-cash-flow value, but also noted that earnings-based multiples make the shares appear expensive. This conflicting signal may be contributing to caution after the stock’s substantial one-year gain.
• Negative Sentiment: Execution and safety risks remain. Zorevunersen’s data are from open-label early-stage studies and require confirmation in later trials. LEQEMBI’s subcutaneous formulation also carries injection-related reactions and still requires MRI monitoring for amyloid-related imaging abnormalities, potentially limiting uptake.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.